Biohaven Pharmaceutical Holding Company Ltd.

NYSE BHVN

Biohaven Pharmaceutical Holding Company Ltd. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD 614.97 M

Biohaven Pharmaceutical Holding Company Ltd. Net Cash Used Provided By Financing Activities is USD 614.97 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 23.77% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Biohaven Pharmaceutical Holding Company Ltd. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 496.85 M, a 3,419.43% change year over year.
Biohaven Pharmaceutical Holding Company Ltd. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -14.97 M, a -101.68% change year over year.
Biohaven Pharmaceutical Holding Company Ltd. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 892.99 M.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

NYSE: BHVN

Biohaven Pharmaceutical Holding Company Ltd.

CEO	Dr. Vladimir Coric M.D.
IPO Date	Sept. 23, 2022
Location	United States
Headquarters	215 Church Street
Employees	239
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Clinical Trials Drugstores & Retail Pharmacies Mental Health

Description

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Key trends

Past 5 years